Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Raymond James Maintains Strong Buy on Envestnet, Raises Price Target to $111
Raymond James analyst Patrick O'Shaughnessy maintains Envestnet (NYSE:ENV) with a Strong Buy and raises the price target from $101 to $111.
Envestnet Shares Spike To Session High, Up 4%; ‘Envestnet sale process down to two PE bidders’ -Article From Citywire
https://citywireusa.com/registered-investment-advisor/news/envestnet-sale-process-down-to-two-pe-bidders-sources/a2384590
UBS, Envestnet, iCapital Highlight Launch Of Alternatives Exchange Platform, ‘providing private market investment opportunities to Envestnet’s client base with more than 35 funds available from managers across geographies and strategies’
UBS (NYSE:UBS), Envestnet (NYSE:ENV), and iCapital1 today announced that the Alternatives Exchange is now live, providing private market investment opportunities to Envestnet's client base with more than 35 funds
Truist Securities Maintains Buy on Envestnet, Lowers Price Target to $90
Truist Securities analyst Michael Young maintains Envestnet (NYSE:ENV) with a Buy and lowers the price target from $95 to $90.
Recap: Envestnet Q4 Earnings
Envestnet (NYSE:ENV) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Envestnet beat estimated earnings by 2.04%, reporting an EPS of $0.5 versus an estimate of $0.49.
Envestnet Q4 Adj. EPS $0.50 Beats $0.49 Estimate, Sales $319.60M Beat $311.40M Estimate
Envestnet (NYSE:ENV) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.49 by 2.04 percent. This is a 27.54 percent decrease over earnings of $0.69 per share from the same